Nosa Plugs Valuation
Is NOSA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of NOSA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate NOSA's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate NOSA's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for NOSA?
Key metric: As NOSA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is NOSA's PS Ratio? | |
|---|---|
| PS Ratio | 8.4x |
| Sales | SEK 14.96m |
| Market Cap | SEK 126.11m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 7.8x |
| Enterprise Value/EBITDA | -7.9x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does NOSA's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 15.7x | ||
QLINEA Q-linea | 36.8x | 51.1% | SEK 127.6m |
ARCOMA Arcoma | 0.8x | 8.3% | SEK 136.5m |
EPIS B Episurf Medical | 7.9x | 93.5% | SEK 99.4m |
NEOLA Neola Medical | 17.3x | 39.8% | SEK 181.0m |
NOSA Nosa Plugs | 8.4x | 38.5% | SEK 126.1m |
Price-To-Sales vs Peers: NOSA is good value based on its Price-To-Sales Ratio (8.4x) compared to the peer average (15.7x).
Price to Sales Ratio vs Industry
How does NOSA's PS Ratio compare vs other companies in the SE Medical Equipment Industry?
Price-To-Sales vs Industry: NOSA is expensive based on its Price-To-Sales Ratio (8.4x) compared to the Swedish Medical Equipment industry average (4.7x).
Price to Sales Ratio vs Fair Ratio
What is NOSA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 8.4x |
| Fair PS Ratio | 5.7x |
Price-To-Sales vs Fair Ratio: NOSA is expensive based on its Price-To-Sales Ratio (8.4x) compared to the estimated Fair Price-To-Sales Ratio (5.7x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Iconovo
SEK 80.2m
Develops and licenses inhalation medications in Sweden.
ICO
SEK 5.02
7D
-1.6%
1Y
-46.3%
Arcoma
SEK 136.5m
Develops, produces, and provides radiology solutions worldwide.
ARCOMA
SEK 10.95
7D
0.5%
1Y
47.0%
Dignitana
SEK 99.1m
A medical technology company, engages in the development, production, and marketing of medical cooling devices in the United States and internationally.
DIGN
SEK 1.20
7D
10.1%
1Y
-45.5%